In this podcast, Cornelis Winnips, Joerg Moehrle and Manuel Battegay discuss conducting clinical trials in Africa.

Pharma, Product Development Partnerships and academia have significantly different approaches to the conduct of clinical trials. They also have different goals in drug development.

Christian Burri and Eric Nébié talk to Cornelis Winnips (pharma), Joerg Moehrle (Product Development Partnership) and Manuel Battegay (academia) about their perspectives. The three experts share their most successful clinical trial experiences in Africa.

Dr Cornelis Winnips is the Global Program Clinical Head at Novartis based in Switzerland. He is a physician and experienced pharmaceutical executive and has extensive experience in clinical development Phases I-IV. He has also worked in marketing and finance roles both in big-pharma and in start-up environments.

Dr Joerg Moehrle joined the Product Development Partnership Medicines for Malaria Venture (MMV) in 2005. Before that, he had worked in clinical development in the pharmaceutical and biotech industry across a range of indications such as asthma, oncology, inflammatory diseases and neurology. He had left malaria basic research because there was limited interest and funding at the time, and currently he very much appreciates being part of renewed efforts to fight and eradicate this disease.

Professor Manuel E. Battegay is Chief of the Division of Infectious Diseases and Hospital Epidemiology, Department Medicine, University Hospital Basel. He is a Professor of Internal Medicine and Infectious Diseases at the University of Basel and part of the leading COVID-19 task force team at the University Hospital Basel. He particularly worked on HIV and tuberculosis in sub-Saharan Africa. Together with colleagues from the Swiss TPH, he established a HIV/TB clinic in Ifakara, Tanzania.

Téléchargements